Use of Reboxetine in Bulimia Nervosa: A Pilot Study

Abstract

The pharmacological approach to bulimia nervosa is mainly based (BN) on selective serotonin reuptake inhibitors, but many elements suggest the possible involvement of the noradrenergic system in this disorder. The aim of the study was to assess the efficacy of reboxetine – aselective norepinephrine uptake inhibitor – in a sample of bulimicoutpatients, after 3 months of treatment. Twenty-eight of 77consecutively admitted patients with a DSM-IV diagnosis of BN (without Axis I comorbidity) received reboxetine. All patients were assessed at baseline (T0), and after 1 month (T1) and 3 months (T3), respectively, of treatment with reboxetine 4 mg/day. The subjects were administered the following questionnaires: Hamilton Rating Scale for Anxiety (HAM-A) and for Depression (HAM-D), Global Assessment Functioning (GAF), Eating Disorder Inventory-2 (EDI-2) and Body Shape Questionnaire (BSQ). Sixty percent of the patients were responsive to treatment(evaluated as a 50% decrease of bulimic behaviours). After 3 months of treatment, a significant reduction emerged in the scores of various EDI-2 subscales (Bulimia, Drive for Thinness, Body Dissatisfaction, Social Insecurity, Interpersonal Distrust, etc.) and in the BSQ total score. Moreover, depressive symptoms (HAM-D) and Global Functioning (GAF) scores showed a significant improvement. These data support a fast and favourable effect of reboxetine in the treatment of BN, both onsymptoms and psychopathological features. Moreover, the specific and strong action of reboxetine on improvement of social functioning is also supported in this disorder.

Keywords

antidepressants bulimia nervosa drug eating disorders noradrenaline pharmacological treatment reboxetine

Get full access to this article

View all access options for this article.

References

Agras W S , Rossiter E M , Arnow B , Schneider J A , Telch C F , Raeburn S D , Bruce B , Perl M , Koran L M (1992) Pharmacological and cognitive-behavioral treatment for bulimia nervosa: a controlled comparison . Am J Psychiatry 149: 82–87

American Psychiatric Association (1994) DSM-IV-Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DC

American Psychiatric Association Work Group on Eating Disorders (2000) Practice Guideline for the Treatment of Patients with Eating Disorders . Am J Psychiatry 157: 1–39

Anderluh M B , Tchanturia K , Rabe-Hesketh S , Treasure J (2003) Childhood obsessive-compulsive personality traits in adult women with eating disorders: defining a broader eating disorder phenotype . Am J Psychiatry 160: 242–247

Bacaltchuk J , Hay P (2001) Antidepressants versus placebo for people with bulimia nervosa . Cochrane Database Systems Review 4: CD003391-CD003391

Bizeul C , Sadowsky N , Rigaud D (2001) The prognostic value of initial EDI scores in anorexia nervosa patients: a prospective follow-up study of 5–10 years . Eur Psychiatry 16: 232–238

Brambilla F (2001) Aetiopathogenesis and pathophysiology of bulimianervosa: biological bases and implications for treatment . CNS Drugs 15: 119–136

Calandra C , Gulino V , Inserra L , Giuffrida A (1999) The use of citalopram in an integrated approach to the treatment of eating disorders: an open study . Eat Weight Disord 4: 207–222222210

Cooper PJ , Taylor MJ , Cooper Z , Fairburn CG (1986) The development and validation of the Body Shape Questionnaire . Int J Eat Dis 6: 485–494 .

10.

El-Giamal N , de Zwaan M , Bailer U , Lennkh C , Schussler P , Strand A , Kasper S (2000) Reboxetine in the treatment of bulimia nervosa: a report of seven cases . Int Clin Psychopharmacol 15: 351–356

11.

El-Giamal N , de Zwaan M , Bailer U , Strnad A , Schussler P , Kasper S (2003) Milnacipran in the treatment of bulimia nervosa: a report of 16 cases . Eur Neuropsychopharmacol 13: 73–79

12.

Fassino S , Abbate Daga G , Pierò A , Leombruni P , Rovera G G (2001) Anger and personality in eating disorders . J Psychosom Res 51: 757–764

13.

Fassino S , Leombruni P , Abbate Daga G , Brustolin A , Migliaretti G , Cavallo F , Rovera G G (2002) Efficacy of citalopram in anorexia nervosa: a pilot study . Eur Neuropsycho Pharmacol 12: 453–459

14.

First M B , Spitzer R L , Gibbon M , Williams J B W (1995) Structured clinical interview for DSM-IV axis I disorders – outpatient edn (SCID-O/P, version 2.0). Biometric Research, New York State Psychiatric Institute, New York

15.

Fitcher M M , Leibl C , Kruger R , Rief W (1997) Effects of fluvoxamine on depression, anxiety, and other areas of general psychopathology in Bulimia Nervosa . Pharmacopsychiatry 30: 85–92

16.

Frank G K , Kaye W H , Marcus M D (2001) Sertraline in underweight binge eating/purging type eating disorders: five case reports . Int J Eat Dis 29: 495–498

17.

Garner D M , Olmsted M P , Polivy J (1983) Development and validation of a multidimensional eating disorder inventory for anorexia nervosa and bulimia . Int J Eat Dis 2: 15–34

18.

Garner DM (1993) Eating disorder inventory – 2: Professional manual. Psychological Assessment Resources, Odessa, FL

19.

Gorman J M , Sullivan G (2000) Noradrenergic approaches to anti-depressant therapy . J Clin Psychiatry 1: 13–16

20.

Groth-Marnat G (1990) The handbook of psychological assessment, 2nd edn. John Wiley & Sons, New York

21.

Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. Revised, 1976. DHEW Pubblication No. (ADM): 76–338

22.

Hamilton M (1959) The assessment of anxiety states by rating . Br J Med Psychol 32: 50–55

23.

Healy D , Healy H (1998) The clinical pharmacologic profile of reboxetine: does it involve the putative neurobiological substrates of wellbeing? J Affect Disord 51: 313–322

24.

Kordy H , Kramer B , Palmer R L , Papezova H , Pelet J , Richard M , Treasure J (2002) Remission, recovery, relapse, and recurrence in eating disorders: conceptualization and illustration of a validation strategy . J Clin Psychol 58: 833–846

25.

Mitchell J E (1997) Managing medical complications. In Garner M G Garfinkel P E (eds), Handbook of treatment for eating disorders. Guilford Press, New York

26.

Mitchell J E , Maki D D , Adson D E , Ruskin B S , Crow S (1997) The selectivity of inclusion and exclusion criteria in bulimia nervosa treatment studies . Int J Eat Dis 22: 243–252

27.

Mitchell J E , Tareen B , Sheehan W , Agras S , Brewerton T D , Crow S , Devlin M , Eckert E , Halmi K , Herzog D , Marcus M , Powers P , Stinkard A , Walsh B T (2000) Establishing guidelines for Pharmacotherapytrials in bulimia nervosa and anorexia nervosa . Int J Eat Dis 28: 1–7

28.

Montgomery S A (1999) Alternatives to placebo-controlled trials in Psychiatry . Eur Neuropsychopharmacol 9: 265–269

29.

Mucci M (1997) Reboxetine: a review of antidepressant tolerability . J Psychopharmacol 11: S33–37

30.

Romano S J , Halmi K A , Sarkar N P , Koke S C , Lee J S (2002) A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment . Am J Psychiatry 159: 96–102

31.

SPSS Inc. (1998) SPSS base 8.0: application guide. SPSS Inc., Chicago, IL

32.

Steinhausen H C (2002) The outcome of anorexia nervosa in the 20thcentury . Am J Psychiatry 159: 1284–1293

33.

Tse W S , Bond A J (2003) Reboxetine promotes social bonding in healthy volunteers . J Psychopharmacol 17: 189–195

34.

Walsh B T , Agras W S , Devlin M J , Fairburn C G , Wilson G T , Kahn C , Chally M K (2000) Fluoxetine for bulimia nervosa following poor response to psychotherapy . Am J Psychiatry 157: 1332–1334

35.

Wong EH , Sonders MS , Amara SG , Tinholt PM , Piercey MF , Hoffmann WP , Hyslop DK , Franklin S , Porsolt RD , Bonsignori A , Carfagna N , McArthur RA (2000) Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor . Biol Psychiatry 47: 818–829

36.

Wellman P J (2000) Norepinephrine and the control of foodd intake . Nutrition 16: 837–842

37.

Zhu A J , Walsh B T (2002) Pharmacologic treatment of eating disorders . Can J Psychiatry 47: 227–234